Acute ST segment elevation myocardial infarction
Conditions
Interventions
Treatment group:On the basis of routine management, a subcutaneous injection of 140mg of erlotinib and 10mg of rosuvastatin were administered before PCI, followed by a change to 10mg qn.
Control group:Conventional treatment is given, including rosuvastatin 10mg, qn
Sponsors
Liaocheng People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18-75 years old; 2. Meets the diagnostic criteria for acute STEMI; 3. Successful completion of PCI within 12 hours of onset; 4. Have never used PCSK9 inhibitors in the past and have not taken statins within the 30 days prior to enrollment.
Exclusion criteria
Exclusion criteria: 1. Severe cardiac dysfunction or hemodynamic instability; 2. Combined with severe liver and kidney dysfunction; 3. Suffering from malignant tumors or inflammatory diseases; 4. Moderate to severe anemia: hemoglobin<90 g/L; 5. Statins cannot be tolerated or statin use is contraindicated. 6. Allergic to the medication required for this study. 7. I am currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major cardiovascular adverse events (The composite endpoint includes death, recurrent myocardial infarction, unexpected revascularization, stroke, and readmission due to ischemia).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammation(Blood analysis, C-reactive protein, interleukin);ST segment regression on electrocardiogram;Left ventricular ejection fraction;Postoperative TIMI blood flow grading and myocardial color grading;Liver function;Renal function;Blood fat; | — |
Countries
China
Contacts
Public ContactZuolin Fu
Liaocheng People's Hospital
Outcome results
None listed